Using Digital Tools To Unpick The Adherence Problem

An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.

Digital lock opened
• Source: Alamy

As many as a half of patients do not take prescription medicines as prescribed. The Organisation for Economic Co-operation and Development estimates that around 200,000 premature deaths annually in Europe relate to poor medication adherence, which may cost as much as €125bn each year in avoidable hospitalization, emergency care and adult outpatient visits. While there is currently no comprehensive understanding of all the factors that influence patients’ decisions regarding treatment adherence, an EU-funded project hopes to demonstrate that by making information on medicines more accessible and understandable, patients will be more likely to take their medicines correctly, resulting in better health outcomes and quality of life.

The public-private partnership Gravitate-Health group, backed by the EU Innovative Medicines Initiative (IMI2), has the ambitious aim of delivering a...

More from Market Access

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.